Moolec Science Sa · NASDAQ:MLEC
Moolec Science Sa — FY2024 Earnings Presentation
15 slides from Moolec Science Sa's earnings presentation, Oct 2, 2024
Slide 1: Business Update Conference Call
SCIENCE IN FOOD INGREDIENTS Business Update Conference Call 4th Quarter Fiscal Year 2024 October 2, 2024
Slide 2: Disclaimer
Disclaimer SCIENCE IN FOOD INGREDIENTS The information presented herein includes forward-looking statements, projections, and estimates based on Moolec's internal analysis, management estimates, and publicly disclosed information within the industry. These estimates and projections are subject to va
Slide 3: Agenda
Agenda SCIENCE IN FOOD INGREDIENTS 1 FY 2024 Annual Review (Milestones) 2 Financial Overview 3 FY 2025: A Pivotal Year .03 Conference Call 4th Quarter Fiscal Year 2024
Slide 4: 1. FY 2024 Annual Review (Milestones)
SCIENCE IN FOOD INGREDIENTS 1. FY 2024 Annual Review (Milestones)
Slide 5: FY 2024 Annual Review (Milestones)
FY 2024 Annual Review (Milestones) SCIENCE IN FOOD INGREDIENTS Piggy Sooy™ GLASO™ Piggy Sooy™ Level of Expression Trial production on partner FT and seed increase stabilization in T3 seeds processor facility in 3 different US locations Q1 Q3 Q4 Q1 Q3 Q4 Self-owned Molecular Piggy Sooy™ GLASO™ Biolog
Slide 6: FY 2024 Annual Review: Level of Expression Stabilization
FY 2024 Annual Review (Milestones) | 1 half st SCIENCE IN FOOD INGREDIENTS Self-owned Molecular Piggy Sooy™ Level of Expression Biology Labs in the US stabilization in T3 seeds Leveraging on knowledge and Second consecutive generation of high networking of one of the most amounts of animal proteins
Slide 7: FY 2024 Annual Review: USDA-APHIS Approval and Production
FY 2024 Annual Review (Milestones) | 2 half nd SCIENCE IN FOOD INGREDIENTS Piggy Sooy™ USDA-APHIS GLASO™ trial production on GLASO™ 600 acres + Piggy Approval (RSR) partner processor facility Sooy™ FT and seed increase First company to achieve Preliminary testings in third-party toll US campaigns fo
Slide 8: 2. Financial Overview
SCIENCE IN FOOD INGREDIENTS 2. Financial Overview
Slide 9: Financial Highlights for the Full FY2024
Financial Highlights for the Full FY2024 SCIENCE IN FOOD INGREDIENTS Revenue & Other Income1 Cost of Sales1 $5.79 M $4.53 M $0.94 M $1.04 M FY ‘23 FY ‘24 FY ‘23 FY ‘24 SG&A and R&D Expenses Cash used in Operating Activities $9.33 M $9.30 M $7.51 M $6.16 M FY ‘23 FY ‘24 FY ‘23 FY ‘24 1 Ex-IAS 29 .09
Slide 10: 3. FY 2025: A Pivotal Year
SCIENCE IN FOOD INGREDIENTS 3. FY 2025: A Pivotal Year
Slide 11: FY 2025: A Pivotal Year
FY 2025: A Pivotal Year SCIENCE IN FOOD INGREDIENTS Commercial Operational R&D and Product Team Traction Focus Development Consolidation • Volume/Revenue • Upstream & Downstream • Pipeline grow • Operation hub in the US • Sampling yields & quality assurance • Partners/Customers for • Sales & Marketi
Slide 12: Let's redefine the way we produce animal proteins
SCIENCE IN FOOD INGREDIENTS Letˇs redefine the way we produce animal proteins for the good of the planet. Follow us! NASDAQ:MLEC hello@moolecscience.com | ir@moolecscience.com
Slide 13: Consolidated Statements of Operations
Consolidated Statements of Operations SCIENCE IN FOOD INGREDIENTS For the For the Change For the For the Change three months three months % fiscal year fiscal year % ended ended ended ended June June June June 30, 2024 30, 2023 30, 2024 30, 2023 (In thousands of U.S. dollars, (In thousands of U.S. d
Slide 14: Condensed Consolidated Statements of Financial Position
Condensed Consolidated Statements SCIENCE of Financial Position IN FOOD INGREDIENTS As of As of Change June June % 30, 30, 2024 2023 (In thousands of U.S. dollars, unless otherwise noted) Current assets 13,748.4 5,331.8 158% Non-current assets 21,038.5 18,719.4 12% Total assets 34,786.9 24,051.2 45%
Slide 15: Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements SCIENCE of Cash Flows IN FOOD INGREDIENTS For the For the Change fiscal year fiscal year % ended June ended June 30, 2024 30, 2023 (In thousands of U.S, unless otherwise noted) Net cash (used) / generated in operating (9,328.3) (7,511.4) 24% Net cash (used) / genera